Vimarsana
Biggest News Aggregation in the World

David Dible News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from David Dible. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In David Dible Today - Breaking & Trending Today

Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors - Vimarsana News

Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors

Published: January 6, 2023

/PRNewswire/ -- Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment...

Source: prnewswire.com
Related Topics:
United KingdomOxford GlycosciencesFrazer HallJames NobleDouglas ThomsonSandi GreenwoodUniversity Of OxfordGw PharmaceuticalsUniversity Of St AndrewsSutura TherapeuticsCelleron TherapeuticsAdvanced Medical SolutionsChief Executive OfficerCarbohydrate Binding MoleculeInfluenza VirusRespiratory Syncytial VirusDavid Dible
Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio - Vimarsana News

Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing its Expanded Clinical Portfolio

Published: January 3, 2023

/PRNewswire/ -- Molecure S.A. ("Molecure": WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to...

Source: prnewswire.com
Related Topics:
United StatesFrazer HallUnited KingdomWayne State UniversityYale UniversityEleanor PerkinMarcin SzumowskiEli LillyMarta BorkowskaSamson FungMolecure SaSandi GreenwoodUniversity Of FreiburgDepartment Of BiochemistryWarsaw Stock ExchangeUniversity Of MichiganRutgers UniversitySenior Research Fellow At MolecureProcter Gamble PharmaceuticalsVp Research BiologyTrinity College Dublin IrelandFlemish Institute For BiotechnologyMarburg Lung CenterInternational Institute Of MolecularHead Of Clinical Development
Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 3 January 2023 - Vimarsana News

Nordic Nanovector ASA - Notice of Extraordinary General Meeting on 3 January 2023

Published: December 13, 2022

OSLO, Norway, Dec. 13, 2022 /PRNewswire/ -- Nordic Nanovector ASA's ("Nordic Nanovector" or the "Company") largest shareholder North Energy ASA, that now holds 11,518,448 shares in the Company

Source: finanznachrichten.de
Related Topics:
Frazer Hall DavidMalene BrondbergAdvokatfirmaet SelmerInvestor ServicesNordea Bank AbpNomination CommitteeNorwegian Public Limited Liability CompaniesIssuer ServiceNorth EnergyExtraordinary General MeetingNorwegian Public Limited Liability Companies ActTjuvholmen AllEuronext Securities OsloDavid DibleCitigate Dewe RogersonSecurities Trading
Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022 - Vimarsana News

Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022

Published: December 5, 2022

/PRNewswire/ -- Molecure S.A. ("Molecure": WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to...

Source: prnewswire.com
Related Topics:
United StatesEleanor PerkinRafal KrenkeCezary SzczylikFrazer HallMarcin SzumowskiMarta BorkowskaSamson FungNicolas BeuzenSandi GreenwoodYale UniversityFlemish Institute For BiotechnologyWarsaw Stock ExchangeInternational Institute Of MolecularUniversity Of MichiganRutgers UniversityHead Of Department Internal MedicineUniversity Of WarsawVp Research BiologyHead Of The Department Clinical OncologyBusiness DevelopmentKey Opinion LeadersOpinion Leader PresentersInternal MedicinePulmonary Diseases
Molecure to begin clinical development of novel dual arginase inhibitor OATD-02 for the treatment of cancer after gaining permission to conduct first clinical trial in Poland - Vimarsana News

Molecure to begin clinical development of novel dual arginase inhibitor OATD-02 for the treatment of cancer after gaining permission to conduct first clinical trial in Poland

Published: November 28, 2022

/PRNewswire/ -- Molecure S.A. ("Molecure") (WSE: MOC) a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and...

Source: prnewswire.com
Related Topics:
Eleanor PerkinFrazer HallSamson FungMarta BorkowskaSandi GreenwoodEuropean Regional Development FundEuropean UnionWarsaw Stock ExchangeOffice For Registration Of Medicinal ProductsPolish OfficeMedicinal ProductsMedical DevicesBiocidal ProductsChief Medical OfficerEuropean Funds Smart GrowthEuropean Regional DevelopmentDavid Dible